The following convention has been used for the classification of frequency: very common ≥ 1/10, common ≥ 1/100 and <1/10, uncommon ≥ 1/1000 and <1/100, rare ≥1/10000 and <1/1000, very rare <1/10000.
Lacidipine (Lacipil) is usually well tolerated. Some individuals may experience minor side-effects which are related to its known pharmacological action of peripheral vasodilation. Such effects, indicated by a hash (#), are usually transient and usually disappear with continued administration of Lacidipine (Lacipil) at the same dosage.
Psychiatric disorders: Very rare: Depression.
Nervous system disorders: Common: Headache, dizziness. Very rare: Tremor.
Cardiac disorders: Common: Palpitation, tachycardia. Uncommon: Aggravation of underlying angina, syncope, hypotension.
As with other dihydropyridines aggravation of underlying angina has been reported in a small number of individuals, especially at the start of treatment. This is more likely in patients with symptomatic ischaemic heart disease.
Vascular disorders: Common: Flushing.
Gastrointestinal disorders: Common: Stomach discomfort, nausea. Uncommon: Gingival hyperplasia.
Skin and subcutaneous tissue disorders: Common: Skin rash (including erythema and itching). Rare: Angioedema, urticaria.
Renal and urinary disorders: Common: Polyuria.
General disorders and administration site conditions: Common: Asthenia, oedema.
Investigations: Common: Reversible increase in alkaline phosphatase (clinically significant increases are uncommon).
View ADR Monitoring Form